Research programme: antibacterials - Oscient Pharmaceuticals/Schering-Plough

Drug Profile

Research programme: antibacterials - Oscient Pharmaceuticals/Schering-Plough

Alternative Names: Staphylococcus aureus therapies - Oscient Pharmaceuticals/Schering-Plough; Antibacterials research programme - Oscient Pharmaceuticals/Schering-Plough

Latest Information Update: 16 Nov 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oscient Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 25 Oct 2007 This programme is still in active development
  • 13 Apr 2004 Genome Therapeutics is now called Oscient Pharmaceuticals
  • 12 Feb 2004 Genome Therapeutics has merged with GeneSoft Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top